See more : Meier Tobler Group AG (0QQK.L) Income Statement Analysis – Financial Results
Complete financial analysis of Aytu BioPharma, Inc. (AYTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aytu BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Superhouse Limited (SUPERHOUSE.NS) Income Statement Analysis – Financial Results
- Nextdoor Holdings, Inc. (KVSB) Income Statement Analysis – Financial Results
- SoundHound AI, Inc. (SOUN) Income Statement Analysis – Financial Results
- Pacific Booker Minerals Inc. (BKM.V) Income Statement Analysis – Financial Results
- Norben Tea & Exports Limited (NORBTEAEXP.BO) Income Statement Analysis – Financial Results
Aytu BioPharma, Inc. (AYTU)
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Cost of Revenue | 26.42M | 40.77M | 44.39M | 36.43M | 7.55M | 2.20M | 2.05M | 1.42M | 957.08K | 88.11K | 0.00 | -48.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.59M | 66.63M | 52.28M | 29.20M | 20.08M | 5.12M | 1.61M | 1.80M | 1.61M | 173.67K | 58.93K | 50.00K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 67.39% | 62.04% | 54.08% | 44.49% | 72.67% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | 100.00% | 2,857.14% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.79M | 4.10M | 14.44M | 5.62M | 1.72M | 589.07K | 167.60K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.51M | 28.63M | 31.17M | 25.50M | 19.66M | 0.00 | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 0.00 |
| Selling & Marketing | 26.96M | 41.45M | 38.71M | 30.31M | 11.40M | 0.00 | 0.00 | -242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.47M | 70.08M | 69.88M | 55.81M | 34.80M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| Other Expenses | 7.58M | -4.78M | 4.07M | 6.01M | 4.49M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 7.34K | 4.25K | 2.58K | 2.71K | 0.00 | 0.00 |
| Operating Expenses | 60.57M | 78.96M | 88.39M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Cost & Expenses | 86.26M | 119.73M | 132.77M | 103.87M | 48.57M | 24.17M | 21.50M | 22.08M | 16.77M | 7.89M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Interest Income | 0.00 | 9.00K | 14.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.79M | 0.00 | 147.50M | 0.00 | 0.00 | 0.00 | 749.42K | 2.53M | 5.49M | 114.99K | 45.55K | 4.90K | 3.32K | 3.18K | 3.80K | 3.07K | 0.00 | 2.06K |
| Depreciation & Amortization | 8.27M | 8.82M | 10.15M | 7.70M | 4.59M | 2.24M | 1.85M | 1.84M | 874.79K | 118.20K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.52K | 6.42K |
| EBITDA | -1.01M | -3.51M | -27.96M | -29.04M | -12.21M | -14.12M | -15.25M | -18.13M | -21.81M | -7.51M | -52.71K | -47.47K | -50.21K | -126.86K | -47.28K | -47.54K | -47.47K | -40.47K |
| EBITDA Ratio | -1.25% | -7.07% | 42.70% | -22.08% | -89.07% | -59.69% | -245.22% | -449.95% | -520.19% | -2,870.37% | -10,604.89% | -2,712.69% | -2,868.91% | 0.00% | 0.00% | -2,716.51% | 0.00% | 0.00% |
| Operating Income | -5.25M | -17.07M | 37.22M | -38.24M | -20.94M | -16.85M | -19.70M | -20.13M | -21.70M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Income Ratio | -6.49% | -15.89% | 38.50% | -58.26% | -75.76% | -230.13% | -538.26% | -624.70% | -847.02% | -2,915.53% | -10,770.31% | -2,995.09% | -3,220.34% | 0.00% | 0.00% | -3,189.83% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.82M | 14.00K | 1.02M | 840.00K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.90K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Income Before Tax | -14.08M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.68K | -136.80K | -56.47K | -58.89K | -48.95K | -48.95K |
| Income Before Tax Ratio | -17.38% | -15.88% | -114.08% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1,099.73% | -2,959.45% | -10,847.61% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| Income Tax Expense | 1.77M | -57.00K | -110.00K | 259.00K | -9.92M | 20.04M | -2.13M | 1.11M | 8.48M | -23.91K | -813.70K | 911.31K | 3.32K | 3.18K | -548.00 | 3.07K | 2.19K | 2.06K |
| Net Income | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.68K | -136.80K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Income Ratio | -19.56% | -15.88% | -113.97% | -88.81% | -13.39% | -644.33% | -278.36% | -698.67% | -1,099.73% | -2,950.32% | -9,466.80% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| EPS | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| EPS Diluted | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| Weighted Avg Shares Out | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation...
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August...
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3...
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman...
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024...
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for...
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO,...
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million...
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for...
Source: https://incomestatements.info
Category: Stock Reports